Table 4.
JAK2 inhibitors under clinical development in patients with MF
NA indicates not available.
*Includes patients receiving placebo (COMFORT-I) or “best-available therapy” (COMFORT-II).
JAK2 inhibitors under clinical development in patients with MF
NA indicates not available.
*Includes patients receiving placebo (COMFORT-I) or “best-available therapy” (COMFORT-II).
